Literature DB >> 30396388

Risk factors increasing blood pressure in Japanese colorectal cancer patients treated with bevacizumab.

M Nishihara, N Morikawa, S Yokoyama, K Nishikura, M Yasuhara, H Matsuo.   

Abstract

Bevacizumab has been reported to increase blood pressure. However, the factors, including patient characteristics and laboratory data contributing to this side effect remain unclear. Therefore, we investigated the relationships between increased blood pressure and bevacizumab administration, patient characteristics, and laboratory data. Between April 2007 and January 2018, factor analysis was retrospectively conducted by monitoring increases in blood pressure, the status of bevacizumab administration, patient characteristics, and laboratory data before the first administration in Japanese patients with colorectal cancer who satisfied the criteria for this study. Sixty-seven patients were included, 34 of whom (50.7%) had an increase in blood pressure after bevacizumab administration. On univariate analysis, liver metastasis, antihypertensive drug use, systolic blood pressure at rest before the first bevacizumab administration, body mass index, creatinine, and blood platelet count were significantly different between the two groups. Multivariate analysis was conducted using increased blood pressure as an objective variable and the factors extracted by the univariate analysis as explanatory variables. The results suggested that liver metastasis, antihypertensive drugs, systolic blood pressure at rest before the first bevacizumab administration, and creatinine were associated with the increase in blood pressure. Furthermore, a log-rank test performed based on Kaplan-Meier curves demonstrated that liver metastasis in patients not taking antihypertensive drugs and antihypertensive drug use in patients without liver metastasis were significantly associated with increased blood pressure. Additionally, liver metastasis in patients with antihypertensive drug use was significantly associated with increased blood pressure. Our findings suggest that liver metastasis and antihypertensive drug use, which was previously reported, are risk factors for increased blood pressure.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30396388     DOI: 10.1691/ph.2018.8664

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

1.  Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.

Authors:  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
Journal:  Support Care Cancer       Date:  2022-10-11       Impact factor: 3.359

2.  Analyzing adverse drug reaction using statistical and machine learning methods: A systematic review.

Authors:  Hae Reong Kim; MinDong Sung; Ji Ae Park; Kyeongseob Jeong; Ho Heon Kim; Suehyun Lee; Yu Rang Park
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

3.  Analyzing non-cancer causes of death of colorectal carcinoma patients in the US population for the years 2000-2016.

Authors:  Lili Lu; Li Ma; Xianbin Zhang; Christina Susanne Mullins; Michael Linnebacher
Journal:  Cancer Med       Date:  2020-12-13       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.